When a clinical trial fails to enroll on time, the problem rarely starts with recruitment. It starts with the distance between where patients receive care and where research happens. Traditional site models ask patients to travel to separate facilities, follow separate schedules, and see separate physicians — models that embedded clinical research was designed to replace. That friction compounds at every step, and it shows up in the data.
Embedded clinical research closes that distance. By integrating trial protocols directly into the environments where patients already receive ongoing care, this model produces enrollment rates, retention figures, and data quality that conventional approaches struggle to match. For pharmaceutical sponsors and CRO clinical operations teams evaluating delivery partners, understanding how that integration works — and why it matters for data — is worth the attention.
What Embedded Clinical Research Actually Means
The term gets used loosely, so it helps to be precise. In a genuine embedded model, the investigator is the patient’s own treating physician. The trial does not pull the patient away from their usual care relationship; it runs through it. Visits, assessments, and protocol milestones happen within the same clinical setting where that physician already manages the patient’s condition.
This is structurally different from a site management organization placing a coordinator inside a practice. In that arrangement, the research infrastructure is overlaid on the practice from outside. In a true embedded model, the investigator holds both roles — and that distinction has direct consequences for data quality, patient behavior, and the representativeness of the population enrolled.
At FOMAT Medical, this approach operates under the Embedded Research Organization (ERO) model, developed across approximately 40 investigator sites in seven U.S. states. The sites are not referral networks. They are practices where investigators carry active patient panels in the therapeutic areas under study.
Why Routine Care Integration Changes Enrollment
Enrollment timelines are where most sponsors first notice the difference. When investigators are also treating physicians, they encounter eligible patients continuously — not only when a trial is actively recruiting. A gastroenterologist managing a panel of patients with Crohn’s disease is in a position to identify candidates at every appointment, not only when a recruiter flags them through an external database.
That proximity also changes the conversation. Patients who already trust their physician are more likely to hear about a trial and consider it. The physician already knows their history, their comorbidities, their medication burden, and what their life looks like outside the clinic. The eligibility assessment is faster and more accurate. The informed consent discussion happens inside an existing relationship rather than between a stranger and a wary patient.
The result is a shorter path from identification to enrollment — and a lower rate of screen failures, because the physician is not working from a referral abstract. They know the patient.
For sponsors evaluating Phase II and Phase III delivery partners, this enrollment efficiency matters beyond timelines. It reduces the cost per enrolled patient and limits the pressure to lower inclusion criteria to hit targets — a pressure that compromises data validity in ways that surface later.
The Real-World Data Advantage
Real-world data is a term sponsors and regulators use with increasing frequency, but what constitutes genuinely real-world data depends entirely on how and from whom it was collected. The distinction between trial-generated and real-world evidence has become a central question in regulatory strategy, particularly as payers demand proof of effectiveness beyond controlled trial conditions.
In a conventional trial, patients may modify their behavior during participation in ways that diverge from their usual patterns — partly because they know they are being studied, and partly because the trial environment itself is artificial. They attend more appointments than they otherwise would. They interact with study coordinators who reinforce protocol adherence. They may be healthier than the broader population with the same condition, because recruitment through advertising or referral networks tends to capture more motivated, less burdened patients.
When the trial runs through routine care, those dynamics shift. Embedded clinical research changes the default: patients are already accustomed to the clinical relationship, the rhythm of participation aligns more closely with the rhythm of their actual care, and because investigators are drawing from active patient panels rather than recruitment campaigns, the enrolled population reflects a broader cross-section of people living with the condition — including those with comorbidities, polypharmacy, and socioeconomic circumstances that trials typically underrepresent.
That representativeness is not a secondary concern. Regulators and payers increasingly scrutinize whether trial populations reflect the real-world populations that will ultimately use the therapy. Data generated in an embedded model is better positioned to answer that question.
Retention and Protocol Adherence Over Time
Trial dropout is one of the most persistent problems in clinical research, and it is not evenly distributed. Patients who drop out are rarely a random subset of the enrolled population. They tend to be the patients with more complicated lives, less social support, and greater barriers to participation — which means dropout systematically distorts the remaining dataset toward patients who are easier to treat and easier to retain. Embedded clinical research addresses this at the structural level, not through added incentives or coordinator outreach.
Embedded clinical research mitigates dropout through the same mechanism that strengthens enrollment: the patient’s relationship with their physician. A patient who feels some ambivalence about continuing is more likely to work through that ambivalence with a physician they trust than to simply stop responding to calls from a coordinator they see four times a year. The physician can address concerns in the context of the patient’s overall care, reframe the decision appropriately, and document the outcome accurately.
Higher retention rates are not just operationally convenient. They reduce missing data, preserve statistical power, and limit the analytical adjustments that introduce their own interpretive problems into the final dataset. ClinicalTrials.gov data consistently shows that dropout-related protocol amendments are among the most common mid-study modifications — each one a signal that the original enrollment and retention assumptions did not hold.
For sponsors managing long-duration protocols or studies in therapeutic areas with high symptom burden — gastroenterology, endocrinology, respiratory, nephrology — retention is often the variable that determines whether a trial produces a usable dataset or an inconclusive one.
What This Means for Diversity in Trial Populations
The FDA’s guidance on diversity in clinical trial populations reflects a recognition that underrepresentation is not just an equity issue. It is a scientific validity issue. A therapy that was studied primarily in one demographic subgroup may perform differently across the real-world patient population — and a label that cannot address that variability has limited clinical utility.
Embedded clinical research at established community practices reaches populations that academic medical centers and research-only sites often do not. FOMAT’s approach to diversity in clinical trials is grounded in this structure: when investigators are the patients’ own physicians at practices embedded in their communities, the enrolled population reflects that community rather than the population that self-selects for research.
This matters at the IND stage, at the NDA stage, and in payer negotiations that follow approval. A trial dataset with genuine population diversity is a more defensible asset at every downstream decision point.
How Sponsors and CROs Should Evaluate Embedded Partners
Not every site that describes itself as embedded operates under a true integrated care model. The questions worth asking center on the actual relationship between investigator and patient population. In genuine embedded clinical research, that relationship predates the trial and extends beyond it.
Does the investigator hold an active patient panel in the therapeutic area, or are they primarily a research physician who sees patients only in trial contexts? Is the trial visit integrated into routine care scheduling, or does it require a separate track? How does the site handle a patient whose condition changes during the trial — through the same physician who understands the whole clinical picture, or through a handoff to separate care?
The answers determine whether the site’s enrollment and retention performance will hold across a full study duration, and whether the data it generates will reflect the real-world population the sponsor needs to characterize.
FOMAT’s network across California, Texas, North Carolina, Maryland, Michigan, New Mexico, and Colorado is built on investigators who meet this standard — physicians managing active therapeutic area panels where research is one component of an ongoing care relationship, not the entire relationship.
The Data Quality Argument in Summary
The case for embedded clinical research as a data quality strategy comes down to three structural advantages that are difficult to replicate through other means.
First, the patient population is drawn from ongoing care rather than recruitment campaigns, which means enrollment is faster and the enrolled population is more representative. Second, the investigator’s knowledge of the patient’s full clinical picture reduces screen failures, improves protocol adherence, and increases the accuracy of adverse event reporting. Third, the care relationship that makes enrollment possible also makes retention more durable — preserving dataset integrity across the full study duration.
For sponsors and CRO teams evaluating where to place trial operations, those three factors translate directly into timeline confidence, dataset quality, and the defensibility of findings. Embedded clinical research is not a recruitment strategy dressed up as a research philosophy. It is a structural approach to producing data that holds up.
To learn more about how FOMAT’s ERO model supports Phase II and III programs across therapeutic areas, contact our team.